This study reported and statistically analyzed psychometric data on PTSD symptoms collected during 80 psychiatric evaluations of patients applying to the New Mexico Medical Cannabis Program from 2009 to 2011. Greater than 75% reduction in CAPS symptom scores were reported when patients were using cannabis compared to when they were not. Read More
In 2011, researchers in Israel published the first study evaluating the effect of cannabis on patients with Crohn’s disease. All patients stated that consuming cannabis had a positive effect, ameliorating disease activity and reducing the need for other conventional medications. The researchers hypothesized that the observed beneficial effect in this study may be due to the anti-inflammatory properties of cannabis, but additional effects of cannabinoids may also play a role. Read More
In 2011, Nature Publishing Group released an article by researchers at the University of California, San Francisco, who undertook a study of twenty-one individuals with chronic pain to delineate the synergistic effects of cannabinoids and opioids. The study concluded that vaporized cannabis augments the analgesic effects of opioids without significantly altering plasma opioid levels. The combination may allow for opioid treatment at lower doses with fewer side effects. Read More
In July 2015, Neurotherapeutics published an article about Autism spectrum disorder (ASD), presenting a modern view of the endocannabinoid (eCB) system, and alterations of its main components in human patients and animal models relevant to ASD. Our understanding of eCB signaling in autism is still in its infancy compared with other disorders of the central nervous system or of peripheral tissues, where eCB-based therapies have already reached preclinical and clinical phases. However, research in this field is rapidly evolving, and novel drugs able to hit specifically a distinct element of the eCB system are being developed at a surprising speed. Read More
A study by researchers at Harvard Medical School was published in Molecular Cancer Therapeutics in 2011 characterizing the mechanism underlying the antitumoral properties of cannabidiol (CBD). This study showed that CBD induced both apoptosis and autophagy-induced death in breast cancer cells and inhibited the survival of both estrogen receptor-positive and estrogen receptor-negative breast cancer cell lines. These data enhance the desirability of CBD as an anticancer agent, because they suggest that CBD preferentially kills breast cancer cells, while minimizing damage to normal breast tissue.
In 2005, the British Journal of Pharmacology published a study evaluating the ability of cannabidiol (CBD) to impair the migration of tumor cells and thus act as a potential antitumoral compound. The results of the study reinforce the evidence of antitumoral properties of CBD, demonstrating its ability to limit tumor invasion, although the mechanism of its pharmacological effects remains to be clarified. This antimigratory property, together with the known antiproliferative and apoptotic features of CBD, strengthen the evidence for its use as a potential antitumoral agent.
An article in JAMA: Physicians should educate patients about medical marijuana to ensure that it is used appropriately and that patients will benefit from its use. To effectively do this, they need to educate themselves. Read More
From an original investigation published in JAMA, there was moderate-quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity. Read More
Management of chronic pain is one of the most common reasons given by individuals seeking medical cannabis. However, very little information exists about the concurrent use of cannabis and prescription pain medication (PPM). This study fills this gap in knowledge by systematically comparing medical cannabis users who use or do not use PPM, with an emphasis on Read More
From The British Journal of Cardiology, this 2015 editorial, by neurologist and cannabis research pioneer Dr. Ethan Russo, explores the cardiovascular risks associated with cannabis, suggesting that ultra-low THC and therapeutic phytocannabinoid dosing are cardio protective, while high doses of THC and high levels of stimulation of the CB1 receptor pose cardiovascular risks. Read More